Drug intelligence / Profile preview

ADX63365

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

**ADX63365** is an investigational small molecule developed by Addex Pharmaceuticals as a **positive allosteric modulator (PAM)** of the **metabotropic glutamate receptor 5 (mGluR5)**. It enhances glutamate signaling at this G protein-coupled receptor (GPCR) to potentially treat schizophrenia by addressing both positive symptoms and cognitive deficits, offering advantages over existing antipsychotics that inadequately manage cognition. Licensed exclusively worldwide to Merck & Co., Inc. in 2008 for schizophrenia and undisclosed indications, it was orally available and in preclinical/late preclinical development as of 2009-2010, with no further public progress reported.

Other names: ADX 63365ADX63365ADX-63365

Targets

GRM5 (Metabotropic glutamate receptor 5)

Beyond the preview

Go deeper on ADX63365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX63365.

Explore the full profile